Photo by imonnet from unsplash
This cohort study compares the overall survival between patients who currently or formerly smoked with patients who never smoked and initiated pembrolizumab monotherapy as first-line treatment for advanced non–small lung… Click to show full abstract
This cohort study compares the overall survival between patients who currently or formerly smoked with patients who never smoked and initiated pembrolizumab monotherapy as first-line treatment for advanced non–small lung cancer.
Keywords:
first line;
treatment advanced;
overall survival;
line treatment;
advanced non;
survival patients
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!